2020
ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. Cell Rep Med. 2020;1(9):100158.
Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer. 2020;20(6):323-342.
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov. 2020;10(3):440-459.
Accelerated thrombin times are associated with thrombotic risk. Am J Hematol. 2020;95(5):E113-E114.
Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer. Cancer Prev Res (Phila). 2020;13(12):979-988.
Functional impact of cancer patient-associated Bcl-xL mutations. MedComm (Beijing). 2020;1(3):328-337.
A novel method for the laboratory workup of anaphylactic transfusion reactions in haptoglobin-deficient patients. Transfusion. 2020;60(4):682-687.
Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer. Int J Cancer. 2020;146(10):2694-2702.
Transient commensal clonal interactions can drive tumor metastasis. Nat Commun. 2020;11(1):5799.
